Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity and Common Stock Purchase Warrants (Tables)

v3.19.3
Stockholders' Equity and Common Stock Purchase Warrants (Tables)
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Schedule of Convertible Preferred Stock, Common Stock and Warrants Issued and Outstanding

Shares of Common Stock Issued and Outstanding      
Issued and outstanding as of December 31, 2018     27,142,979  
Registered offerings     5,480,000  
Conversions - Senior Secured Convertible Note issued December 27, 2018     3,850,427  
Employee Stock Purchase Plan (“ESPP”)     82,772  
Issued and outstanding as of September 30, 2019     36,556,178  

Schedule of Outstanding Warrants to Purchase Common Stock

The following table summarizes outstanding warrants to purchase common stock of the Company at the dates indicated:

 

    Common Stock Purchase Warrants Issued and Outstanding at
    September 30, 2019    

Weighted Average

Exercise

Price /Share

    December 31, 2018    

Weighted

Average

Exercise

Price

    Expiration
Date
Equity classified warrants                                    
Series Z Warrants     16,815,039     $     1.60       16,815,039     $     1.60     April 2024
UPO - Series Z Warrants     53,000     $ 1.60       53,000     $ 1.60     January 2022
Series W Warrants     381,818     $ 5.00       381,818     $ 5.00     January 2022
Series S Warrants     1,199,383     $ 0.01       1,199,383     $ 0.01     June 2032
Total     18,449,240     $ 1.57       18,449,240     $ 1.57      

Schedule of Noncontrolling Interest

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity for the periods indicated is as follows:

 

   

Nine Months Ended

September 30,

2019

   

Year Ended December 31,

2018

 
NCI - equity (deficit) - beginning of period   $ (161,512 )   $  
Investment in majority-owned subsidiary           1,812  
Net loss attributable to NCI     (500,622 )     (204,072 )
Lucid Diagnostics Inc. 2018 Equity Plan - stock-based compensation     141,778       40,748  
NCI - equity (deficit) - end of period   $ (520,356 )   $ (161,512 )